CABACabaletta Bio, Inc.

3.130USD+0.97%Mkt Cap: 530.68M $P/E:

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabt…